MedTrace Logo

The Role of Microparticles as a Biomarker

NCT02626663 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2019-02-19

No results posted yet for this study

Summary

The investigators propose to characterize MPs in aHUS and TTP both at the onset and throughout treatment. The investigators believe that the number, size, and cell origin of MPs will differ between these two diseases. The hypothesis is that endothelial derived MPs will be higher in number and comprise a larger portion of the MP population in aHUS and that platelet MPs will comprise a larger number and greater proportion of MPs in TTP. The investigators believe that MP identity and number can be used to reliably differentiate between aHUS and TTP at disease onset.

Conditions

  • Atypical Hemolytic Uremic Syndrome
  • Thrombotic Thrombocytopenic Purpura
  • Microparticles
  • Microangiopathic Hemolytic Anemia

Sponsors & Collaborators

  • University of Rochester

    lead OTHER

Principal Investigators

  • Amy Schmidt, MD PhD · University of Rochester

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2020-12-31
Completion
2022-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626663 on ClinicalTrials.gov